Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring HER2 Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report

PURPOSE: HER2 overexpression has been identified in approximately 14% of bladder adenocarcinomas. However, until now, there has been no approved standard targeted therapy for bladder adenocarcinoma patients harboring HER2 genetic alteration. CASE PRESENTATION: We presented a case of a 64-year-old ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaolu, Hu, Wenjing, Xie, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244354/
https://www.ncbi.nlm.nih.gov/pubmed/32547059
http://dx.doi.org/10.2147/OTT.S247515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244354/
https://www.ncbi.nlm.nih.gov/pubmed/32547059
http://dx.doi.org/10.2147/OTT.S247515

Ejemplares similares